Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations

NCT03513562 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Ibrutinib Resistance

Interventions

DRUG: Ibrutinib
OTHER: Laboratory Biomarker Analysis
DRUG: Venetoclax

Sponsor

Ohio State University Comprehensive Cancer Center